TET2 Mutations Drive Aging Blood Clones, Inflammation and Divergent Cancer Immunotherapy Outcomes
A new review explains why TET2 loss fuels age-related blood clones and inflammation yet can strengthen engineered CAR-T cells, depending on cell type and context.
Résumé
TET2 is an enzyme that removes methyl tags from DNA, and its loss-of-function mutations are among the most common drivers of age-related clonal hematopoiesis (CHIP). This narrative review argues that TET2 acts as a context-dependent regulator, not just a demethylase. Its effects depend on cell type, direction of alteration, functional layer (catalytic, scaffold-like, metabolic) and microenvironment. In blood stem cells, TET2 loss favors clonal expansion and myeloid skewing. In macrophages, it amplifies NLRP3, IL-1β and IL-6 signaling, which is linked to atherosclerosis and heart failure. In solid tumors and CAR-T cells, effects vary, with possible benefits for T-cell persistence but long-term clonal risk. Human evidence is mostly associative; mechanisms come largely from animal and cell models.
Résumé détaillé
Why it matters: Clonal hematopoiesis of indeterminate potential (CHIP) becomes common with age, appearing in about 9.5% of people aged 70-79 and 18.4% of those aged 90 and older. TET2 is one of the most frequently mutated genes, alongside DNMT3A and ASXL1. TET2-mutant CHIP is linked to blood cancers, cardiovascular disease and other inflammatory conditions, so understanding TET2 has implications for healthy aging.
What the review covers: This is a narrative, mechanism-oriented review, not a new experiment. It organizes TET2 biology into three layers: canonical oxidation of 5-methylcytosine and enhancer control; catalytic-independent chromatin scaffolding (for example recruiting Hdac2 to repress IL-6, and Sin3a at enhancers); and metabolic regulation by α-ketoglutarate, vitamin C, 2-hydroxyglutarate and itaconate. It interprets divergent findings through four variables: cell type, direction of alteration, functional layer, and microenvironmental or therapeutic context. It also separates human association evidence from experimental, preclinical and hypothesis-generating data.
Key results: TET2 loss in blood stem cells increases self-renewal and myeloid bias, and inflammatory signals such as IL-1 and IL-6 can select for mutant clones. A germline IL6R variant was associated with reduced TET2 clonal expansion in a longitudinal human study. TET2 mutations are common in MDS and AML, with outcomes depending on co-mutations. They are hallmark events in angioimmunoblastic T-cell lymphoma and often signal poor prognosis in DLBCL. In macrophages, TET2 deficiency increases IL-1β, IL-6 and NLRP3 inflammasome activity and weakens inflammatory resolution, and in mouse models it accelerates atherosclerosis. Human studies link clonal hematopoiesis to worse outcomes in aortic stenosis, heart failure, stroke, cardiogenic shock and hypertrophic cardiomyopathy, as well as to gout, COPD and autoimmunity, though not all associations are TET2-specific.
Implications: Therapeutic ideas are early. Colchicine appears to act downstream by dampening inflammatory effector pathways rather than eliminating mutant clones. Ruxolitinib may blunt cytokine feedback in selected contexts but remains exploratory. A small phase 2 trial of high-dose intravenous vitamin C in TET2-mutated CCUS saw no responses at week 20. In engineered T cells, TET2 disruption can enhance memory-like persistence and antitumor activity but may carry long-term oncogenic risk.
Caveats: Human data mainly show association, and causality rests largely on mouse and cell models. TET2-mutant CHIP is a risk-enriched state, not an inevitable path to malignancy. Different mutation types may affect different TET2 functions. Any treatment strategies need validation in prospective, genotype-stratified trials.
Principales conclusions
- TET2 loss-of-function mutations are among the most frequent drivers of age-related CHIP, which reaches 18.4% prevalence in people aged 90 and older.
- TET2-deficient macrophages show elevated IL-1β, IL-6 and NLRP3 inflammasome activity, with impaired Hdac2-mediated IL-6 repression prolonging inflammation.
- Human cohorts link clonal hematopoiesis to heart failure, atherosclerosis, stroke and aortic stenosis outcomes, but causality is shown mainly in mouse models.
- Metabolites shape TET2 output: vitamin C and α-ketoglutarate support it, while 2-hydroxyglutarate and itaconate inhibit it; a phase 2 vitamin C trial showed no responses.
- TET2 disruption can boost CAR-T persistence and antitumor activity but raises concern about long-term clonal or oncogenic risk.
Méthodologie
This is a narrative, mechanism-oriented review synthesizing human genetic and clinical studies, animal models, cell-based experiments and early clinical observations. The authors organize evidence by four variables (cell type, direction of alteration, functional layer, therapeutic context) and label evidence level to avoid overstating causality. It is not a systematic review and reports no formal search or quality-grading protocol.
Limites de l'étude
Evidence linking TET2-mutant CHIP to disease in humans is largely associational, and many cardiovascular findings concern clonal hematopoiesis overall rather than TET2 specifically. Mechanistic conclusions rely heavily on mouse and cell models that may not fully translate to people. As a narrative review, it may reflect selection bias, and the CAR-T and solid-tumor findings are still preliminary and context-specific.
Ce résumé vous a plu ?
Recevez les dernières recherches sur la longévité dans votre boîte de réception chaque semaine.
Saisissez votre e-mail pour vous abonner :